Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1194611 | 0.81 | KMT2A (0.52) | KMT2AMEN1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL3979519 | 0.81 | KMT2A (0.50) | KMT2AMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL1169955 | 0.80 | CA1 (0.48) | KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1958907 | 0.78 | KMT2A (0.40) | KMT2AMEN1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL1958962 | 0.77 | KIF11 (0.51) | KMT2AL3MBTL1 | |
| SCHEMBL4250031 | 0.77 | TSHR (0.47) | KMT2AMEN1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL6649907 | 0.75 | L3MBTL1 (0.49) | KMT2AMEN1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL3247012 | 0.74 | ALDH1A1 (0.50) | KMT2AMEN1ALDH1A1KDM4ECYP3A4 | |
| SCHEMBL5745852 | 0.73 | BCHE (0.42) | KMT2AMEN1ALDH1A1SMN1; SMN2CYP3A4 | |
| Acetic Acid SCHEMBL28858384 | 0.71 | KMT2A (0.51) | KMT2AMEN1ALDH1A1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1625112-B1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20070010559-A1 | Indole derivatives for use as chemical uncoupler | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | US | disclosed |
| EP-1689710-A1 | INDOLE DERIVATIVES FOR USE AS CHEMICAL UNCOUPLER | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| US-20060128662-A1 | Novel compounds for treatment of obesity | NOVO NORDISK A/S (DK) | 2006-06-15 | — | — | US | disclosed |
| EP-1625112-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005051908-A1 | INDOLE DERIVATIVES FOR USE AS CHEMICAL UNCOUPLER | NOVO NORDISK A/S (DK) | 2005-06-09 | — | — | WO | disclosed |
| WO-2004101505-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010559-A1 | Indole derivatives for use as chemical uncoupler | GPR119, IDO2, IDO1 | KMT2A 1438/4885MEN1 4192/4885ALDH1A1 1400/4885 |
| US-20060128662-A1 | Novel compounds for treatment of obesity | GPR119, FABP4, HSD17B4 | KMT2A 2506/4885MEN1 4794/4885ALDH1A1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.